Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C V...(es. On average each patient in the Asah...),Health

Date:6/10/2009

es. On average, each patient in the Asahi study received three DFPP treatments each lasting 3.14 hours. In the study, DFPP was administered once daily for three consecutive days at the outset of SOC therapy and provided an average viral load reduction of 26.1% during each treatment period. Amazingly, the 71.4% and 77.8% cures rates were achieved without any additional DFPP during the remaining SOC treatment regimen. As a result of DFPP treatment outcomes, Asahi has advanced DFPP beyond treatment candidate status to actively marketing the treatment in Japan as the V-RAD system, which Asahi derives from the phrase "Virus Removal and Eradication by DFPP". Additional information can be accessed online at: www.v-rad.jp/en/index.html. I shall keep my comments directed towards the science underlying the V-RAD system and not the animation you will encounter at this website. Regardless, the website is quite informative.

However, there are significant limitations for DFPP as compared to our Hemopurifer(R). Like other approaches to therapeutic filtration, DFPP relies on multiple pumps and filters to indiscriminately remove particles by molecule size. For this reason, DFPP also extracts particles beyond HCV that are required for patient health. The safety profile of DFPP can be further diminished by the need for replacement fluids. In combination, these factors limit the time an HCV-infected patient can be exposed to DFPP treatment.

The advantages of our Hemopurifier(R) as compared to DFPP include the following:

1. The Hemopurifier(R) provides a greater reduction of HCV from circulation during treatment. Our data resulting from over 20 HCV treatments indicates an average viral load reduction of 41% during four-hour treatment applications of the Hemopurifier(R).
2. The Hemopurifier(R) augments the immune response by
   '/>"/>

SOURCE Aethlon Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
3. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. MSU engineering team designs innovative medical device
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
8. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
9. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
10. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
11. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions